Additional Patent Granted for Promising Melanoma
Advanced Life Sciences collaborates with
University of Illinois at Chicago on cancer research
Woodridge, Ill (July 17, 2003) - The U.S. Patent and Trademark
Office has issued an additional patent for the use of betulinic
acid, also known as ALS-357, and its derivatives as a method for
treating cancer. The patent was granted to the University of Illinois
at Chicago (UIC) which is collaborating with Woodridge, Ill-based
Advanced Life Sciences to advance ALS-357 and its derivatives
as anti-cancer agents. The lead ALS-357 compound, has demonstrated
efficacy in animal models to treat and prevent malignant melanoma,
a common, but frequently fatal form of skin cancer.
John Pezzuto, PhD, formerly with UIC's College of Pharmacy and
now dean of Purdue University's College of Pharmacy, Nursing and
Health Services and Tapas K. Das Gupta, MD, PhD, professor and
head of Surgical Oncology at UIC's College of Medicine, are the
primary inventors of this technology. Advanced Life Sciences has
acquired the exclusive worldwide license to commercialize the
technology from the University of Illinois at Chicago.
"This new patent coverage expands Advanced Life Science's
intellectual property portfolio in ALS-357 and its derivatives
as potential anti-cancer agents," said Michael Flavin, PhD,
Chief Executive Officer of Advanced Life Sciences. "Our melanoma
research continues on a productive track and the issuance of this
additional patent serves to increase the number of possible therapeutic
options that are available for investigation."
The patent (No. 6,569,842), which applies to ALS-357 and its
derivatives, was granted for compounds, pharmaceutical compositions
and methods of use in the treatment of cancers including melanoma.
ALS-357 is derived from birch bark and works by promoting the
death of certain cancer cells. It has demonstrated pre-clinical
activity against human melanoma.
Advanced Life Sciences (www.advancedlifesciences.com) is a privately
held biopharmaceutical company engaged in the discovery, development
and commercialization of novel drugs in the therapeutic areas
of infection, cancer, and inflammation using its platform in natural
products and chemical proteomics coupled with expertise in drug